All these findings supported our hypothesis that HER2‐negative gastric cancer is a relatively “hot tumor,” while HER2‐positive gastric cancer is a relatively “cold tumor.” According to our hypothesis, patients with HER2‐positive gastric cancer may not benefit from immune checkpoint inhibitors. The gene discussed is ERBB2; the disease is gastric cancer.